Phenotype
|
Fish
|
Conditions
|
Figures
|
oocyte degenerate, abnormal
|
arihb1225/ihb1225
|
standard conditions
|
Fig. 2
from Yu et al., 2020
|
female organism increased amount, abnormal
|
arihb1225/ihb1225 (AB)
|
standard conditions
|
Fig. 2
from Yu et al., 2018
|
ovary transparent, abnormal
|
arihb1225/ihb1225 (AB)
|
standard conditions
|
Fig. 6
from Yu et al., 2018
|
ovary has fewer parts of type oocyte, abnormal
|
arihb1225/ihb1225 (AB)
|
standard conditions
|
Fig. 6
from Yu et al., 2018
|
female organism increased weight, abnormal
|
arihb1225/ihb1225 (AB)
|
standard conditions
|
Fig. 2
from Yu et al., 2018
|
male organism pectoral fin breeding tubercle absent, abnormal
|
arihb1225/ihb1225 (AB)
|
standard conditions
|
Fig. 3
from Yu et al., 2018
|
ovary cyp11a1.1 expression decreased amount, abnormal
|
arihb1225/ihb1225 (AB)
|
standard conditions
|
Fig. 6
from Yu et al., 2018
|
ovarian follicle atretic, abnormal
|
arihb1225/ihb1225 (AB)
|
standard conditions
|
Fig. 6
from Yu et al., 2018
|
ovary foxl2a expression decreased amount, abnormal
|
arihb1225/ihb1225 (AB)
|
standard conditions
|
Fig. 6
from Yu et al., 2018
|
testis cyp19a1a expression increased amount, abnormal
|
arihb1225/ihb1225 (AB)
|
standard conditions
|
Fig. 7
from Yu et al., 2018
|
ovary lacks all parts of type oocyte, abnormal
|
arihb1225/ihb1225 (AB)
|
standard conditions
|
Fig. 6
from Yu et al., 2018
|
testis hsd17b1 expression increased amount, abnormal
|
arihb1225/ihb1225 (AB)
|
standard conditions
|
Fig. 7
from Yu et al., 2018
|
testis has fewer parts of type spermatocyte, abnormal
|
arihb1225/ihb1225 (AB)
|
standard conditions
|
Fig. 4 ,
Fig. S5
from Yu et al., 2018
|
sperm decreased cellular motility, abnormal
|
arihb1225/ihb1225 (AB)
|
standard conditions
|
Fig. 4
from Yu et al., 2018
|
male organism decreased amount, abnormal
|
arihb1225/ihb1225 (AB)
|
standard conditions
|
Fig. 2
from Yu et al., 2018
|
testis transparent, abnormal
|
arihb1225/ihb1225 (AB)
|
standard conditions
|
Fig. 4
from Yu et al., 2018
|
oocyte stage IV decreased amount, abnormal
|
arihb1225/ihb1225 (AB)
|
standard conditions
|
Fig. 6 ,
Fig. S4
from Yu et al., 2018
|
female organism has fewer parts of type oocyte, abnormal
|
arihb1225/ihb1225 (AB)
|
standard conditions
|
Fig. S4
from Yu et al., 2018
|
ovary lhcgr expression decreased amount, abnormal
|
arihb1225/ihb1225 (AB)
|
standard conditions
|
Fig. 6
from Yu et al., 2018
|
spermatogenic cyst decreased size, abnormal
|
arihb1225/ihb1225 (AB)
|
standard conditions
|
Fig. 4
from Yu et al., 2018
|
spermatogenesis arrested, abnormal
|
arihb1225/ihb1225 (AB)
|
standard conditions
|
Fig. 4
from Yu et al., 2018
|
testis cyp17a1 expression increased amount, abnormal
|
arihb1225/ihb1225 (AB)
|
standard conditions
|
Fig. 7
from Yu et al., 2018
|
ovary decreased size, abnormal
|
arihb1225/ihb1225 (AB)
|
standard conditions
|
Fig. 6
from Yu et al., 2018
|
male organism anal fin decreased pigmentation, abnormal
|
arihb1225/ihb1225 (AB)
|
standard conditions
|
Fig. 3
from Yu et al., 2018
|
testis ccnd2a expression decreased amount, abnormal
|
arihb1225/ihb1225 (AB)
|
standard conditions
|
Fig. 5
from Yu et al., 2018
|
testis has fewer parts of type sperm, abnormal
|
arihb1225/ihb1225 (AB)
|
standard conditions
|
Fig. 4 ,
Fig. S5
from Yu et al., 2018
|
testis star expression increased amount, abnormal
|
arihb1225/ihb1225 (AB)
|
standard conditions
|
Fig. 7
from Yu et al., 2018
|
germ cell proliferation decreased occurrence, abnormal
|
arihb1225/ihb1225 (AB)
|
standard conditions
|
Fig. 5
from Yu et al., 2018
|
ovary cyp19a1a expression decreased amount, abnormal
|
arihb1225/ihb1225 (AB)
|
standard conditions
|
Fig. 7
from Yu et al., 2018
|
testis germ line cell apoptotic, abnormal
|
arihb1225/ihb1225 (AB)
|
standard conditions
|
Fig. 5
from Yu et al., 2018
|
visceral fat increased amount, abnormal
|
arihb1225/ihb1225 (AB)
|
standard conditions
|
Fig. S3
from Yu et al., 2018
|
testis has extra parts of type Sertoli cell, abnormal
|
arihb1225/ihb1225 (AB)
|
standard conditions
|
Fig. 4
from Yu et al., 2018
|
testis sox9a expression increased amount, abnormal
|
arihb1225/ihb1225 (AB)
|
standard conditions
|
Fig. 7
from Yu et al., 2018
|
ovarian follicle development arrested, abnormal
|
arihb1225/ihb1225 (AB)
|
standard conditions
|
Fig. 6
from Yu et al., 2018
|
ovary kitlga expression decreased amount, abnormal
|
arihb1225/ihb1225 (AB)
|
control
|
Fig. 6
from Yu et al., 2018
|
female organism female sterile, abnormal
|
arihb1225/ihb1225 (AB)
|
standard conditions
|
Fig. 6
from Yu et al., 2018
|
male organism increased weight, abnormal
|
arihb1225/ihb1225 (AB)
|
standard conditions
|
Fig. 2
from Yu et al., 2018
|
testis degenerate, abnormal
|
arihb1225/ihb1225 (AB)
|
standard conditions
|
Fig. S5
from Yu et al., 2018
|
testis ar expression decreased amount, abnormal
|
arihb1225/ihb1225 (AB)
|
standard conditions
|
Fig. 1
from Yu et al., 2018
|
spermatogenesis delayed, abnormal
|
arihb1225/ihb1225 (AB)
|
standard conditions
|
Fig. 5 ,
Fig. S5
from Yu et al., 2018
|
testis has extra parts of type spermatocyte, abnormal
|
arihb1225/ihb1225 (AB)
|
standard conditions
|
Fig. 5
from Yu et al., 2018
|
male organism ratio female organism, abnormal
|
arihb1225/ihb1225 (AB)
|
standard conditions
|
Fig. 2
from Yu et al., 2018
|
ovary ar expression decreased amount, abnormal
|
arihb1225/ihb1225 (AB)
|
standard conditions
|
Fig. 1
from Yu et al., 2018
|
ovarian follicle degenerate, abnormal
|
arihb1225/ihb1225 (AB)
|
standard conditions
|
Fig. 6
from Yu et al., 2018
|
testis amh expression increased amount, abnormal
|
arihb1225/ihb1225 (AB)
|
standard conditions
|
Fig. 7
from Yu et al., 2018
|
fertilization decreased rate, abnormal
|
arihb1225/ihb1225 (AB)
|
standard conditions
|
Fig. 6
from Yu et al., 2018
|
ovary hsd17b1 expression decreased amount, abnormal
|
arihb1225/ihb1225 (AB)
|
standard conditions
|
Fig. 7
from Yu et al., 2018
|
testis has extra parts of type spermatogonium, abnormal
|
arihb1225/ihb1225 (AB)
|
standard conditions
|
Fig. 4 ,
Fig. 5 ,
Fig. S5
from Yu et al., 2018
|
testis decreased size, abnormal
|
arihb1225/ihb1225 (AB)
|
standard conditions
|
Fig. 4
from Yu et al., 2018
|
ovary cyp17a1 expression decreased amount, abnormal
|
arihb1225/ihb1225 (AB)
|
standard conditions
|
Fig. 7
from Yu et al., 2018
|
spermatogonium increased size, abnormal
|
arihb1225/ihb1225 (AB)
|
standard conditions
|
Fig. 4
from Yu et al., 2018
|
male organism male sterile, abnormal
|
arihb1225/ihb1225 (AB)
|
standard conditions
|
Fig. 4
from Yu et al., 2018
|
oocyte stage III decreased amount, abnormal
|
arihb1225/ihb1225 (AB)
|
standard conditions
|
Fig. 6 ,
Fig. S4
from Yu et al., 2018
|
ovary kitlga expression decreased amount, abnormal
|
arihb1225/ihb1225 (AB)
|
chemical treatment by injection: 17beta-hydroxy-5alpha-androstan-3-one
|
Fig. 6
from Yu et al., 2018
|
testis gsdf expression increased amount, abnormal
|
arihb1225/ihb1225 (AB)
|
standard conditions
|
Fig. 5
from Yu et al., 2018
|
oocyte stage III decreased amount, abnormal
|
arihb1226/ihb1226 (AB)
|
standard conditions
|
Fig. S6
from Yu et al., 2018
|
ovarian follicle atretic, abnormal
|
arihb1226/ihb1226 (AB)
|
standard conditions
|
Fig. S6
from Yu et al., 2018
|
oocyte stage IV decreased amount, abnormal
|
arihb1226/ihb1226 (AB)
|
standard conditions
|
Fig. S6
from Yu et al., 2018
|
ovary lacks all parts of type oocyte, abnormal
|
arihb1226/ihb1226 (AB)
|
standard conditions
|
Fig. S6
from Yu et al., 2018
|
ovary transparent, abnormal
|
arihb1226/ihb1226 (AB)
|
standard conditions
|
Fig. S6
from Yu et al., 2018
|
female organism increased amount, abnormal
|
arihb1226/ihb1226 (AB)
|
standard conditions
|
Fig. 2
from Yu et al., 2018
|
female organism increased weight, abnormal
|
arihb1226/ihb1226 (AB)
|
standard conditions
|
Fig. 2
from Yu et al., 2018
|
male organism decreased amount, abnormal
|
arihb1226/ihb1226 (AB)
|
standard conditions
|
Fig. 2
from Yu et al., 2018
|
male organism anal fin decreased pigmentation, abnormal
|
arihb1226/ihb1226 (AB)
|
standard conditions
|
Fig. 3
from Yu et al., 2018
|
ovary has fewer parts of type oocyte, abnormal
|
arihb1226/ihb1226 (AB)
|
standard conditions
|
Fig. S6
from Yu et al., 2018
|
ovary decreased size, abnormal
|
arihb1226/ihb1226 (AB)
|
standard conditions
|
Fig. S6
from Yu et al., 2018
|
male organism increased weight, abnormal
|
arihb1226/ihb1226 (AB)
|
standard conditions
|
Fig. 2
from Yu et al., 2018
|
ovarian follicle development arrested, abnormal
|
arihb1226/ihb1226 (AB)
|
standard conditions
|
Fig. S6
from Yu et al., 2018
|
female organism female sterile, abnormal
|
arihb1226/ihb1226 (AB)
|
standard conditions
|
Fig. S6
from Yu et al., 2018
|
fertilization decreased rate, abnormal
|
arihb1226/ihb1226 (AB)
|
standard conditions
|
Fig. S6
from Yu et al., 2018
|
male organism ratio female organism, abnormal
|
arihb1226/ihb1226 (AB)
|
standard conditions
|
Fig. 2
from Yu et al., 2018
|
ovarian follicle degenerate, abnormal
|
arihb1226/ihb1226 (AB)
|
standard conditions
|
Fig. S6
from Yu et al., 2018
|
male organism pectoral fin breeding tubercle absent, abnormal
|
arihb1226/ihb1226 (AB)
|
standard conditions
|
Fig. 3
from Yu et al., 2018
|
ovary amh expression amount, ameliorated
|
arihb1225/+; nedd8ihb1227/ihb1227
|
standard conditions
|
Fig. 4
from Yu et al., 2020
|
primordial germ cell normal amount, ameliorated
|
arihb1225/+; nedd8ihb1227/ihb1227
|
standard conditions
|
Fig. 2
from Yu et al., 2020
|
ovary dmrt1 expression amount, ameliorated
|
arihb1225/+; nedd8ihb1227/ihb1227
|
standard conditions
|
Fig. 4
from Yu et al., 2020
|
ovary kitlga expression amount, ameliorated
|
arihb1225/+; nedd8ihb1227/ihb1227
|
chemical treatment by environment: flutamide
|
Fig. 4
from Yu et al., 2020
|
ovary kitlga expression amount, ameliorated
|
arihb1225/+; nedd8ihb1227/ihb1227
|
standard conditions
|
Fig. 4
from Yu et al., 2020
|
pectoral fin breeding tubercle female organism absent, ameliorated
|
arihb1225/+; nedd8ihb1227/ihb1227
|
chemical treatment by environment: flutamide
|
Fig. 3
from Yu et al., 2020
|
pectoral fin breeding tubercle female organism present, ameliorated
|
arihb1225/+; nedd8ihb1227/ihb1227
|
standard conditions
|
Fig. 3
from Yu et al., 2020
|
ovary amh expression amount, ameliorated
|
arihb1225/ihb1225; nedd8ihb1227/ihb1227
|
standard conditions
|
Fig. 4
from Yu et al., 2020
|
ovary dmrt1 expression amount, ameliorated
|
arihb1225/ihb1225; nedd8ihb1227/ihb1227
|
standard conditions
|
Fig. 4
from Yu et al., 2020
|
oocyte degenerate, exacerbated
|
arihb1225/ihb1225; nedd8ihb1227/ihb1227
|
standard conditions
|
Fig. 2
from Yu et al., 2020
|
ovary kitlga expression amount, ameliorated
|
arihb1225/ihb1225; nedd8ihb1227/ihb1227
|
chemical treatment by environment: flutamide
|
Fig. 4
from Yu et al., 2020
|
ovary kitlga expression amount, ameliorated
|
arihb1225/ihb1225; nedd8ihb1227/ihb1227
|
standard conditions
|
Fig. 4
from Yu et al., 2020
|